Araştırma Makalesi
PDF EndNote BibTex Kaynak Göster

Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment

Yıl 2022, Cilt 15, Sayı 3, 571 - 582, 01.07.2022
https://doi.org/10.31362/patd.1051844

Öz

Introduction: It is among the modifiable risk factors for cardiovascular diseases and stroke. In the follow-ups after quitting this habit, it has been shown that there is a decrease in the mortality rate related to the cardiovascular system and an increase in the quality of life of the patients. In this study, it was aimed to investigate the awareness of the drugs used in smoking cessation on patients and healthy individuals. Methods: Our study was planned as cross-sectional. Patients who applied with any complaints and 198 volunteers from healthcare professionals working in the hospital were included. With the questions in the questionnaire, it was aimed to learn the awareness levels about the drugs used in smoking cessation. Results: In our study, it was determined that women and other professionals did not have statistically significant information in the question in which the effects of these drugs on pulse and blood pressure levels were evaluated. The statement that individuals in other occupational groups did not know about the effect of bupropion treatment on this system was found to be statistically significantly higher (p<0.01). Conclusion: Drug treatments have an important place in getting rid of smoking addiction, which is a very important public health problem, and it is known that these treatments are safe even in those with a history of cardiovascular disease. Knowing these treatments and being able to prescribe these drugs safely if their patients are stable will have a very important place in the fight against smoking.

Kaynakça

  • 1. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet, 2017;389:1885–1906.
  • 2. Türk Toraks Derneği Sigara Bırakma Tanı ve Tedavi Uzlaşı Raporu, Ankara 2014. Erişim yeri:http://www.toraks.org.tr/book.aspx ?list=1655&menu=240 Erişim tarihi: 10.10.2018.
  • 3. Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Araştırmaları Genel Müdürlüğü Sağlık İstatistikleri Yıllığı 2017. Erişim yeri: http://ohsad.org/wpcontent/uploads/2018/09/27344saglikistatistikleri-yilligi-2017-haberbultenipdf.pdf Erişim tarihi: 01.10.2018.
  • 4. Hackshaw A, Morris JK, Boniface S et al. Low cigarette consumption and risk of coronary heart disease and stroke: metaanalysis of 141 cohort studies in 55 study reports. BMJ, 2018;360:5855.
  • 5. Critchley JA, Capewell S.(2003). Mortality riskreduction associated with smoking cessation inpatients with coronary heart disease: a systematicreview. JAMA, 2003;290: 86–97.
  • 6. Wilson K, Gibson N, Willan A et al.Effect ofsmoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med, 2000;160:939–944.
  • 7. Buchanan DM, Arnold SV, Gosch KL et al.. Association of smoking status with angina and health-related quality of life after acute myocardial infarction. Circ Cardiovasc Qual Outcomes, 2015;8:493–500.
  • 8. Jha P, Ramasundarahettige C, Landsman V et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med, 2013;368:341–350.
  • 9. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation, 2014;129:28–41.
  • 10. Mahmarian JJ, Moye LA, Nasser GA et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol, 1997;30:125–130.
  • 11. Ottervanger JP, Festen JM, de Vries AG, Stricker BH. (1995). Acute myocardial infarction while using the nicotine patch. Chest, 1995;107:1765–1766.
  • 12. Ropchan GV, Sanfilippo AJ, Ford SE. Aortic dissection and use of the nicotine patch: a case involving a temporal relationship. Can J Cardiol, 1997;13:525–528.
  • 13. Van der Klauw MM, Van Hillo B, Van den Berg WH et al. (1996). Vasculitis attributed to the nicotine patch (Nicotinell). Br J Dermatol, 1996;134:361–364.
  • 14. Dacosta A, Guy JM, Tardy B et al.Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J, 1993;14:1709–1711.
  • 15. Pierce Jr JR. Stroke following application of a nicotine patch. Ann Pharmacother, 1994;28:402.
  • 16. Rigotti NA, Thorndike AN, Regan S et al. (2006). Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med, 2006;119:1080–1087.
  • 17. Mills EJ, Thorlund K, Eapen S et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation, 2014;129:28–41.
  • 18. Roose SP. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J, 2000;140:84–88.
  • 19. Roose SP, Dalack GW, Glassman AH et al.Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry, 1991;148:512–516.
  • 20. Benowitz NL, Pipe A, West R, et al.. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: A randomized clinical trial. JAMA Intern Med, 2018;178:1–11.
  • 21. Berkesoğlu C, Ozgur ES, Demir AU. Sigara bırakma başarısını etkileyen faktörler. Mersin Univ Saglık Bilim Derg 2018;11(3).
  • 22. Osler M, Prescott E. Psychosocial, behavioural and determinants of succesful smoking cessation: a longitudinal study of Danish adults. Tobacco Control 1998;7(3):262-267.
  • 23. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;18(4):CD006103.
  • 24. Gonzales D, Rennard SI, Nides M et al.Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustainedrelease buprpion and placebo for smoking cessation. A randomized controlled trial. JAMA, 2006;296(1):47-55.

Sigara bırakma tedavisinde kullanılan ilaçların bilgi ve farkındalık düzeylerinin değerlendirilmesi

Yıl 2022, Cilt 15, Sayı 3, 571 - 582, 01.07.2022
https://doi.org/10.31362/patd.1051844

Öz

Giriş: Sigara Dünya genelinde yaklaşık 1 milyar insan tarafından kullanılan ve her yıl 6 milyondan fazla bireyin ölümüne sebep olan bir alışkanlık olarak karşımıza çıkmaktadır. Kardiyovasküler hastalıklar ve inmede değiştirilebilir risk faktörleri içinde yer almaktadır. Bu alışkanlığın bırakılmasının ardından yapılan takiplerde kardiyovasküler sistem ile ilgili mortalite oranında düşme olduğu ve hastaların yaşam kalitelerinde artış olduğu gösterilmiştir. Bu çalışmada sigara bıraktırmada kullanılan ilaçların hastalar ve sağlıklı bireyler üzerinde farkındalığının araştırılması amaçlanmıştır. Yöntem: Çalışmamız kesitsel olarak planlanmıştır. Herhangi bir şikayetle başvuran hastalar ve hastanede çalışan sağlık profesyonellerinden 198 gönüllü çalışmaya dahil edildi. Ankette yer alan sorular ile sigara bırakmada kullanılan ilaçlarla ilgili farkındalık düzeylerinin öğrenilmesi amaçlanmıştır. Bulgular: Çalışmamızda, bu ilaçların nabız ve tansiyon düzeylerine etkilerinin değerlendirildiği soruda, kadın ve diğer profesyonellerin istatistiksel olarak anlamlı bilgilere sahip olmadığı belirlendi. Diğer meslek gruplarındaki bireylerin bupropion tedavisinin bu sistem üzerindeki etkisini bilmedikleri ifadesi istatistiksel olarak anlamlı derecede yüksek bulundu (p<0.01). Sonuç: Çok önemli bir halk sağlığı sorunu olan sigara bağımlılığından kurtulmada ilaç tedavileri önemli bir yer tutmakta ve bu tedavilerin kardiyovasküler hastalık hikayesi olanlarda dahi güvenli olduğu bilinmektedir. Hekimlerin de bu tedavileri bilmesi hastaları stabil ise güvenle bu ilaçları reçete edebilmesi sigara kullanımı ile mücadelede çok önemli bir yer tutacaktır.

Kaynakça

  • 1. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet, 2017;389:1885–1906.
  • 2. Türk Toraks Derneği Sigara Bırakma Tanı ve Tedavi Uzlaşı Raporu, Ankara 2014. Erişim yeri:http://www.toraks.org.tr/book.aspx ?list=1655&menu=240 Erişim tarihi: 10.10.2018.
  • 3. Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Araştırmaları Genel Müdürlüğü Sağlık İstatistikleri Yıllığı 2017. Erişim yeri: http://ohsad.org/wpcontent/uploads/2018/09/27344saglikistatistikleri-yilligi-2017-haberbultenipdf.pdf Erişim tarihi: 01.10.2018.
  • 4. Hackshaw A, Morris JK, Boniface S et al. Low cigarette consumption and risk of coronary heart disease and stroke: metaanalysis of 141 cohort studies in 55 study reports. BMJ, 2018;360:5855.
  • 5. Critchley JA, Capewell S.(2003). Mortality riskreduction associated with smoking cessation inpatients with coronary heart disease: a systematicreview. JAMA, 2003;290: 86–97.
  • 6. Wilson K, Gibson N, Willan A et al.Effect ofsmoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med, 2000;160:939–944.
  • 7. Buchanan DM, Arnold SV, Gosch KL et al.. Association of smoking status with angina and health-related quality of life after acute myocardial infarction. Circ Cardiovasc Qual Outcomes, 2015;8:493–500.
  • 8. Jha P, Ramasundarahettige C, Landsman V et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med, 2013;368:341–350.
  • 9. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation, 2014;129:28–41.
  • 10. Mahmarian JJ, Moye LA, Nasser GA et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol, 1997;30:125–130.
  • 11. Ottervanger JP, Festen JM, de Vries AG, Stricker BH. (1995). Acute myocardial infarction while using the nicotine patch. Chest, 1995;107:1765–1766.
  • 12. Ropchan GV, Sanfilippo AJ, Ford SE. Aortic dissection and use of the nicotine patch: a case involving a temporal relationship. Can J Cardiol, 1997;13:525–528.
  • 13. Van der Klauw MM, Van Hillo B, Van den Berg WH et al. (1996). Vasculitis attributed to the nicotine patch (Nicotinell). Br J Dermatol, 1996;134:361–364.
  • 14. Dacosta A, Guy JM, Tardy B et al.Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J, 1993;14:1709–1711.
  • 15. Pierce Jr JR. Stroke following application of a nicotine patch. Ann Pharmacother, 1994;28:402.
  • 16. Rigotti NA, Thorndike AN, Regan S et al. (2006). Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med, 2006;119:1080–1087.
  • 17. Mills EJ, Thorlund K, Eapen S et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation, 2014;129:28–41.
  • 18. Roose SP. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J, 2000;140:84–88.
  • 19. Roose SP, Dalack GW, Glassman AH et al.Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry, 1991;148:512–516.
  • 20. Benowitz NL, Pipe A, West R, et al.. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: A randomized clinical trial. JAMA Intern Med, 2018;178:1–11.
  • 21. Berkesoğlu C, Ozgur ES, Demir AU. Sigara bırakma başarısını etkileyen faktörler. Mersin Univ Saglık Bilim Derg 2018;11(3).
  • 22. Osler M, Prescott E. Psychosocial, behavioural and determinants of succesful smoking cessation: a longitudinal study of Danish adults. Tobacco Control 1998;7(3):262-267.
  • 23. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;18(4):CD006103.
  • 24. Gonzales D, Rennard SI, Nides M et al.Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustainedrelease buprpion and placebo for smoking cessation. A randomized controlled trial. JAMA, 2006;296(1):47-55.

Ayrıntılar

Birincil Dil İngilizce
Konular Tıp
Yayınlanma Tarihi Ekim 2022
Bölüm Araştırma Makalesi
Yazarlar

Mustafa ÇAM> (Sorumlu Yazar)
CANAKKALE ONSEKIZ MART UNIVERSITY
0000-0003-3116-203X
Türkiye


Ercan AKŞİT>
CANAKKALE ONSEKIZ MART UNIVERSITY
0000-0002-4478-4324
Türkiye

Yayımlanma Tarihi 1 Temmuz 2022
Kabul Tarihi 8 Nisan 2022
Yayınlandığı Sayı Yıl 2022, Cilt 15, Sayı 3

Kaynak Göster

Bibtex @araştırma makalesi { patd1051844, journal = {Pamukkale Tıp Dergisi}, eissn = {1308-0865}, address = {Pamukkale Üniversitesi Tıp Fakültesi Eğitim Blokları Kınıklı kampüsü 20070 Kınıklı, Denizli}, publisher = {Pamukkale Üniversitesi}, year = {2022}, volume = {15}, number = {3}, pages = {571 - 582}, doi = {10.31362/patd.1051844}, title = {Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment}, key = {cite}, author = {Çam, Mustafa and Akşit, Ercan} }
APA Çam, M. & Akşit, E. (2022). Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment . Pamukkale Tıp Dergisi , 15 (3) , 571-582 . DOI: 10.31362/patd.1051844
MLA Çam, M. , Akşit, E. "Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment" . Pamukkale Tıp Dergisi 15 (2022 ): 571-582 <https://dergipark.org.tr/tr/pub/patd/issue/68347/1051844>
Chicago Çam, M. , Akşit, E. "Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment". Pamukkale Tıp Dergisi 15 (2022 ): 571-582
RIS TY - JOUR T1 - Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment AU - Mustafa Çam , Ercan Akşit Y1 - 2022 PY - 2022 N1 - doi: 10.31362/patd.1051844 DO - 10.31362/patd.1051844 T2 - Pamukkale Tıp Dergisi JF - Journal JO - JOR SP - 571 EP - 582 VL - 15 IS - 3 SN - -1308-0865 M3 - doi: 10.31362/patd.1051844 UR - https://doi.org/10.31362/patd.1051844 Y2 - 2022 ER -
EndNote %0 Pamukkale Tıp Dergisi Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment %A Mustafa Çam , Ercan Akşit %T Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment %D 2022 %J Pamukkale Tıp Dergisi %P -1308-0865 %V 15 %N 3 %R doi: 10.31362/patd.1051844 %U 10.31362/patd.1051844
ISNAD Çam, Mustafa , Akşit, Ercan . "Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment". Pamukkale Tıp Dergisi 15 / 3 (Temmuz 2022): 571-582 . https://doi.org/10.31362/patd.1051844
AMA Çam M. , Akşit E. Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment. Pam Tıp Derg. 2022; 15(3): 571-582.
Vancouver Çam M. , Akşit E. Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment. Pamukkale Tıp Dergisi. 2022; 15(3): 571-582.
IEEE M. Çam ve E. Akşit , "Evaluation of knowledge and awareness levels of drugs used in smoking cessation treatment", Pamukkale Tıp Dergisi, c. 15, sayı. 3, ss. 571-582, Tem. 2022, doi:10.31362/patd.1051844
Creative Commons Lisansı
Pamukkale Tıp Dergisi, Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı ile lisanslanmıştır